Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 5,818 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EXTEND Clear all
Withdrawn Phase 1 Interventional

A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

NCT02633657
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Redwood City, California • St Louis, Missouri • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675
View directory record Official record
Conditions
Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
7 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sustaining Aviator Performance During Extended Operational Flight

NCT04697901
View directory record Official record
Conditions
Transcranial Direct Current Stimulation
Interventions
Active Transcranial Direct Current Stimulation (tDCS), Sham Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
United States Army Aeromedical Research Laboratory
Federal
Eligibility
18 Years to 40 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Fort Rucker, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 18, 2026, 8:19 AM EDT
Terminated No phase listed Observational

A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

NCT05819112
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
14,799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Not applicable Interventional Results available

Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes

NCT03398902
View directory record Official record
Conditions
PreDiabetes
Interventions
Sleep extension, Habitual sleep
Behavioral · Other
Lead sponsor
New York University
Other
Eligibility
21 Years to 64 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 18, 2026, 8:19 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Plasma Extension

NCT06416072
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Alzheimer's Disease (AD)
Interventions
NAV4694
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 80 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo for Risankizumab SC, Risankizumab IV, Placebo for Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
111
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

NCT00757237
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI), Tobramycin Inhalation Solution (TIS)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tuscon, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 18, 2026, 8:19 AM EDT
Not yet recruiting Phase 3 Interventional

Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

NCT06973629
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis
Interventions
Debamestrocel - MSC-NTF (NurOwn), Placebo
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
15
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

NCT01683266
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
82
States / cities
Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 1 Interventional

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

NCT04246866
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration
Interventions
GEM103
Biological
Lead sponsor
Gemini Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy

NCT03032172
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Months to 60 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
4
States / cities
Palo Alto, California • Orlando, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 18, 2026, 8:19 AM EDT
Active, not recruiting Phase 2 Interventional

Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

NCT05824728
View directory record Official record
Conditions
Parkinson Disease Psychosis
Interventions
AGB101
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Spencer's Technique on Shoulder Function

NCT06447493
View directory record Official record
Conditions
Shoulder
Interventions
Osteopathic Manipulative Treatment-Spencer's Technique (Modified), Rest
Other
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Withdrawn Phase 4 Interventional

Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer

NCT04741204
View directory record Official record
Conditions
Breast Cancer Stage, Insulin Resistance, Racial Bias
Interventions
Metformin Extended Release Oral Tablet
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

NCT02408549
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide Tablet, Lacosamide Oral Solution
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
4 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
16
States / cities
Little Rock, Arkansas • Santa Monica, California • Colorado Springs, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

NCT05103332
View directory record Official record
Conditions
Hypertension
Interventions
Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
74
States / cities
Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

NCT00914641
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban IR, Apixaban MR1, Apixaban MR2, Apixaban MR3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 18, 2026, 8:19 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

NCT06975722
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SAR442970, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Escondido, California • Lancaster, California • Thousand Oaks, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Terminated Phase 2 Interventional

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04816604
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
GB002 (seralutinib), Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
Gossamer Bio USA, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 8:19 AM EDT
Withdrawn Phase 1 Interventional

Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma

NCT05341947
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Activated T cells
Biological
Lead sponsor
Jeremy Rudnick, M.D
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 18, 2026, 8:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Entrainment Between Clinician and Patient During Palpation

NCT03579238
View directory record Official record
Conditions
Doctor Patient Relation
Interventions
CV4, touching
Procedure
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 18, 2026, 8:19 AM EDT